Global single use bioreactor market is estimated to witness high growth owing to increasing adoption of disposable bioreactors and cost-effectiveness
The Single Use Bioreactor Market is estimated to be valued at USD 3.51 billion in 2024 and with CAGR of 18% over the forecast period 2024-2030. The market is witnessing high growth owing to increasing adoption of disposable bioreactors over stainless steel bioreactors. Disposable bioreactors offer advantages such as reduced validation requirements, lower capital investment, lower cleaning and sterilization costs, and easier scale-up.
Increasing adoption of single-use technologies driving market growth
The single-use bioreactor market is witnessing significant growth due to the increasing adoption of single-use technologies across various industry verticals such as biopharmaceuticals, food & beverage and others. Single-use bioreactors offer various advantages over stainless steel bioreactors such as lower capital investment, reduced validation requirements, flexibility in production and lesser risk of cross-contamination. Biopharmaceutical companies are increasingly preferring single-use bioreactors as they reduce facility footprints and enable faster production turnarounds. This has boosted the demand for single-use bioreactors significantly. Moreover, with growing biosimilar development and advancement in cell and gene therapy research, the adoption of single-use bioreactors is expected to rise further during the forecast period.
Significant cost savings driving increased outsourcing of biopharmaceutical production
Another key driver for the single-use bioreactor market is the significant cost savings achieved by outsourcing biopharmaceutical production to contract manufacturing organizations (CMOs). Large biopharma companies are outsourcing more production to CMOs as it enables them to focus on core areas of drug development while benefiting from the flexibility, expertise and cost efficiencies offered by CMOs. CMOs extensively use single-use bioreactors as they are more suitable for producing small batch sizes on demand. This is fueling the demand for single-use bioreactors from CMOs. Moreover, single-use bioreactors allow CMOs to quickly adjust their production capacity as per changing market demands without significant capital investment in capacity expansion. This has boosted outsourcing and contract manufacturing, thereby positively impacting the single-use bioreactor market. Growing Demand from Surface Coatings Industry is Boosting Market Growth.
High initial costs limiting adoption among small companies
A major restraint hampering the growth of single-use bioreactor market is the high initial costs associated with single-use systems. The disposable bags, tubing, filters and other component come at a premium compared to conventional stainless-steel bioreactors which are reusable. This high initial capital investment poses significant challenges for small & medium biotech companies and academic institutes with limited budgets to adopt single-use bioreactors. Additionally, the costs of validations and waste disposal also add to the overall expenditures. Therefore, the high initial costs are holding back smaller players from transitioning to single-use technologies and limiting the overall market growth.
Difficulties in sterilizing single-use components hindering market growth
Ensuring proper sterilization of disposable single-use components such as bags, tubing, and filters is also a challenge restraining the growth of single-use bioreactor market. The gamma radiation used for sterilizing stainless steel tanks may damage the polymeric films and plastic containers used in single-use systems. This has led to numerous compatibility issues. Moreover, new sterilization techniques such as autoclaving and wet sterilization are also difficult to apply on single-use flexible films and plastic bags. The lack of standardized and reliable sterilization methods for various components is a key concern holding back the adoption of single-use bioreactors. Considerable efforts are underway to address these difficulties and introduce improved sterilization technologies.
Growing demand for continuous manufacturing opening new opportunities
The demand for continuous manufacturing of biopharmaceuticals using single-use bioreactors is opening new avenues of growth for the market. Several biologics manufacturers are transitioning from batch-style to continuous manufacturing as it enhances productivity and efficiency. The flexibility of single-use bioreactors in setting up continuous manufacturing workflows makes them particularly suitable for this application. Leading players are actively developing novel single-use systems optimized for integrated continuous manufacturing. This emerging application segment is expected to provide significant opportunities for stakeholders to commercialize innovative offerings catering to continuous bioprocessing requirements.
Cell and gene therapy boom poised to revolutionize market dynamics
The booming cell and gene therapy sector is another major growth opportunity for stakeholders in the single-use bioreactor market. As the number of cell and gene therapy clinical trials and approvals increase exponentially, there is urgent need for scalable manufacturing capacity. Contract biomanufacturers and companies in this domain are actively pursuing single-use technologies due to advantages such as preventing cross-contamination. Additionally, single-use bioreactors simplify complicated gene therapy processes and enable on-demand manufacturing of personalized treatments. This represents a disruptive growth lever for players to introduce novel single-use systems catering to cell and gene therapy production requirements.
Link: https://www.coherentmarketinsights.com/market-insight/single-use-bioreactor-market-5358
Key Developments
- On 28 March 2024, Getinge, A medtech company expands its bioreactor portfolio with larger single-use systems.Getinge introduces the Single-Use Production Reactor (SUPR) system, initially available in 50-liter and 250-liter sizes.
- In June 2022, mAbxience, biotechnology company enhanced their cGMP (Current Good Manufacturing Practice) facility in León, Spain by installing an additional ABEC 4,000L CSR bioreactor, following the successful delivery of the first 4,000L CSR bioreactor in 2021. mAbxience opted for ABEC's single-use technology to expand its CDMO (contract development and manufacturing organization) business and capacity.
- In May 2022, RD-Biotech, a Contract Research Organization (CRO) specializing in plasmid DNA (pDNA) production for early-phase clinical trials, collaborated with Pall Corporation to provide single-use solutions and purification technology to facilitate the manufacturing of industrially relevant volumes of GMP-grade pDNA.
- In April 2020, Celltainer Biotech BV, A life science equipment company announced intentions to collaborate with PAN-Biotech, as part of a strategic alliance aimed at providing comprehensive solutions for cell culture processes.
Key Players
Sartorius Stedim Biotech, Thermo Fisher Scientific, Danaher, Merck KgaA, Celltainer Biotech BV, Getinge AB, Eppendorf AG, Cellexus, PBS Biotech Inc., Distek Inc., ABEC, Able Corporation & Biott Corporation, G&G Technologies Inc., Solida Biotech GmbH, Satake Chemical Equipment Mfg., Ltd., Stobbe Pharma GmbH, and bbi-biotech GmbH.
